Q4 2025 · 13F-HR
Andera Partnersholdings as filed
Filed 2026-02-17 · accession 0001757283-26-000007
$176.6M
Reported value
5
Positions
2025-12-31
Period end
The Brief · Andera Partners · Q4 2025
AI · grounded in 13F
Andera Partners established five new positions to reach a total AUM of $176.6M. The largest addition was a $67.4M stake in Kestra Med Technologies Ltd KMTS. The fund also initiated positions in Mineralys Therapeutics Inc MLYS for $57.8M and Evommune Inc EVMN for $32.5M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G52441105 | KMTS | KESTRA MED TECHNOLOGIES LTD | $67.4M | 38.1% | 2,540,106 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $57.8M | 32.7% | 1,591,917 | Common | SOLE |
| 30054Y107 | EVMN | EVOMMUNE INC | $32.5M | 18.4% | 1,897,362 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $10.5M | 5.97% | 78,125 | Common | SOLE |
| 46124U107 | IVA | INVENTIVA SA | $8.5M | 4.79% | 1,818,181 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.